Exelixis, Inc. — Form 10-K Summary
Period clarification: The supplied filing is Exelixis’s fiscal 2020 Form 10-K, not a 2019 Q4 filing. Fiscal 2020 ended January 1, 2021 (reported as December 31, 2020); the comparison year ended January 3, 2020. Fiscal 2019 had 53 weeks versus 52 weeks in 2020.
Business context
Exelixis is an oncology-focused biotechnology company. Its principal commercial franchise is cabozantinib: CABOMETYX for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC), and COMETRIQ for medullary thyroid cancer. The company also receives collaboration revenue from products including COTELLIC and MINNEBRO. CABOMETYX plus OPDIVO received U.S. approval for first-line advanced RCC in January 2021, after year-end.
Financial performance
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Total revenue | $987.5 million | $967.8 million | +2% |
| Net product revenue | $741.6 million | $760.0 million | -2% |
| License revenue | $167.3 million | $165.9 million | +1% |
| Collaboration services revenue | $78.7 million | $41.9 million | +88% |
| Research and development expense | $547.9 million | $337.0 million | +63% |
| Selling, general and administrative expense | $293.4 million | $228.2 million | +29% |
| Income from operations | $110.1 million | $369.5 million | -70% |
| Net income | $111.8 million | $321.0 million | -65% |
| Diluted earnings per share | $0.35 | $1.02 | |
| Operating cash flow | $209.0 million | $527.0 million | -60% |
Gross margin was 95%, compared with 96% in 2019. CABOMETYX net sales were $718.7 million, down 2%; COMETRIQ net sales were $22.9 million, down 14%. Management attributed CABOMETYX volume weakness partly to fewer prescriptions and market softness, including COVID-19 effects. Increased collaboration reimbursements and milestones largely offset lower product sales at the total-revenue level. Expense growth—especially clinical-trial spending, licensing and collaboration costs, and personnel—drove the sharp decline in operating and net income. The 2019 comparison also included an additional fiscal week.
At year-end, cash, cash equivalents and investments totaled $1.539 billion, up from $1.389 billion; working capital was $1.241 billion. Current assets were $1.445 billion and current liabilities $204.7 million. The balance sheet reports no conventional borrowings; long-term liabilities included $49.1 million of operating lease liabilities. Investing cash flow was negative $131.2 million and financing cash flow negative $25.1 million. The filing states available resources and expected revenues should fund operations for at least 12 months after filing.
Fourth-quarter 2020 revenue was $270.1 million, operating income $24.3 million and net income $28.4 million. The third quarter recorded an operating loss of $42.6 million and net loss of $32.0 million, attributed primarily to higher clinical, collaboration and personnel costs relative to prior quarters.
Material changes and outlook
- Research and development spending rose substantially as Exelixis expanded cabozantinib trials and invested in pipeline programs and licensing arrangements.
- Management projected 2021 net product revenue to increase, driven principally by CABOMETYX plus OPDIVO and higher selling prices. It expected gross margin to remain consistent with 2020.
- Management expected 2021 license revenue and collaboration services revenue to decline, reflecting fewer anticipated milestones and lower projected development-cost reimbursements, respectively.
- Management expected R&D and SG&A expenses to increase in 2021, and projected an effective tax rate of 20%–22%.
- Clinical catalysts included planned 2021 COSMIC-312 results and potential filing activity for differentiated thyroid cancer; management also identified a possible 2021 accelerated-approval filing for mCRPC, conditional on supporting clinical data and regulatory feedback.
Risks, contingencies and unusual items
- Business growth depends heavily on CABOMETYX’s commercial performance, continued payer coverage and reimbursement, and successful clinical development and approvals in additional indications.
- COVID-19 had a modest reported impact during 2020, including reduced prescriptions and trial disruptions; prolonged or worsening effects could impede enrollment, operations, sales and supply.
- MSN Pharmaceuticals is pursuing FDA approval of generic CABOMETYX tablets. Exelixis filed patent-infringement lawsuits; the consolidated case was scheduled for trial in May 2022. The filing says the outcome and potential loss cannot be determined.
- COSMIC-311 met its progression-free-survival co-primary endpoint. By contrast, the post-marketing EXAMINER study for medullary thyroid cancer did not meet its primary endpoint; Exelixis said it would continue marketing COMETRIQ under its existing approval.
- Exelixis relies on collaboration partners for international commercialization and portions of clinical development, and on third parties for manufacturing. Pricing pressure, competition, regulatory uncertainty, cyber risks and intellectual-property challenges are material risks.
- The company reported a $5.1 million adjustment to 2020 selling, general and administrative expense for branded prescription drug fees related to earlier sales years. No material off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm that this FY2020 10-K, rather than a 2019 Q4 filing, is the intended document.
- Track CABOMETYX prescription volume, net pricing, rebates and discounts, particularly following the first-line RCC combination approval.
- Assess whether clinical spending and licensing investments produce the anticipated trial results, approvals and commercial returns.
- Monitor the MSN patent litigation and the potential timing and impact of generic competition.
- Compare 2021 revenue and expense trends with management’s outlook, noting that milestone revenue can vary materially by period.
- Review cash generation, lease commitments—including the planned additional campus—and any changes to liquidity or capital needs.